Citadel Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $309K | Sell |
88,100
-46,000
| -34% | -$189K | ﹤0.01% | 10404 |
|
|
2025
Q4 | $452K | Buy |
134,100
+107,400
| +402% | +$279K | ﹤0.01% | 9277 |
|
|
2025
Q3 | $35K | Buy |
26,700
+2,300
| +9% | +$2.38K | ﹤0.01% | 12348 |
|
|
2025
Q2 | $17.5K | Buy |
24,400
+12,600
| +107% | +$9.89K | ﹤0.01% | 12132 |
|
|
2025
Q1 | $17.3K | Sell |
11,800
-1,200
| -9% | -$2.86K | ﹤0.01% | 13242 |
|
|
2024
Q4 | $57.6K | Buy |
13,000
+5,500
| +73% | +$22.3K | ﹤0.01% | 12235 |
|
|
2024
Q3 | $30.9K | Buy |
7,500
+3,700
| +97% | +$19.9K | ﹤0.01% | 12405 |
|
|
2024
Q2 | $24.8K | Sell |
3,800
-550,100
| -99% | -$3.89M | ﹤0.01% | 12447 |
|
|
2024
Q1 | $4.82M | Buy |
553,900
+412,000
| +290% | +$5M | ﹤0.01% | 4005 |
|
|
2023
Q4 | $1.62M | Buy |
141,900
+132,700
| +1,442% | +$1.31M | ﹤0.01% | 5744 |
|
|
2023
Q3 | $88.6K | Buy |
9,200
+2,900
| +46% | +$28.4K | ﹤0.01% | 11044 |
|
|
2023
Q2 | $67K | Buy |
6,300
+1,800
| +40% | +$19.3K | ﹤0.01% | 11452 |
|
|
2023
Q1 | $47.3K | Sell |
4,500
-23,700
| -84% | -$265K | ﹤0.01% | 12228 |
|
|
2022
Q4 | $349K | Buy |
+28,200
| New | +$320K | ﹤0.01% | 8979 |
|
|
2022
Q1 | – | Sell |
-46,500
| Closed | -$542K | – | 14084 |
|
|
2021
Q4 | $542K | Buy |
46,500
+17,300
| +59% | +$212K | ﹤0.01% | 9498 |
|
|
2021
Q3 | $381K | Sell |
29,200
-42,800
| -59% | -$553K | ﹤0.01% | 10533 |
|
|
2021
Q2 | $927K | Buy |
72,000
+42,700
| +146% | +$489K | ﹤0.01% | 8560 |
|
|
2021
Q1 | $328K | Buy |
29,300
+16,200
| +124% | +$171K | ﹤0.01% | 10632 |
|
|
2020
Q4 | $149K | Buy |
+13,100
| New | +$143K | ﹤0.01% | 9949 |
|
|
2020
Q3 | – | Sell |
-40,700
| Closed | -$420K | – | 10389 |
|
|
2020
Q2 | $420K | Buy |
+40,700
| New | +$417K | ﹤0.01% | 7366 |
|
|
2020
Q1 | – | Sell |
-10,100
| Closed | -$134K | – | 9870 |
|
|
2019
Q4 | $134K | Buy |
+10,100
| New | +$111K | ﹤0.01% | 8419 |
|
|
2019
Q2 | – | Sell |
-22,328
| Closed | -$253K | – | 9503 |
|
|
2019
Q1 | $253K | Sell |
22,328
-10,029
| -31% | -$112K | ﹤0.01% | 7855 |
|
|
2018
Q4 | $281K | Buy |
32,357
+7,044
| +28% | +$80.8K | ﹤0.01% | 7379 |
|
|
2018
Q3 | $391K | Sell |
25,313
-10,029
| -28% | -$159K | ﹤0.01% | 7119 |
|
|
2018
Q2 | $566K | Buy |
35,342
+16,238
| +85% | +$240K | ﹤0.01% | 6160 |
|
|
2018
Q1 | $247K | Buy |
19,104
+7,045
| +58% | +$87.8K | ﹤0.01% | 7025 |
|
|
2017
Q4 | $151K | Buy |
+12,059
| New | +$158K | ﹤0.01% | 7269 |
|
|
2017
Q3 | – | Sell |
-15,641
| Closed | -$247K | – | 7759 |
|
|
2017
Q2 | $247K | Buy |
+15,641
| New | +$227K | ﹤0.01% | 6227 |
|
|
2016
Q1 | – | Sell |
-3,463
| Closed | -$34K | – | 7344 |
|
|
2015
Q4 | $34K | Sell |
3,463
-3,104
| -47% | -$30K | ﹤0.01% | 7583 |
|
|
2015
Q3 | $57K | Buy |
6,567
+1,075
| +20% | +$10K | ﹤0.01% | 7485 |
|
|
2015
Q2 | $55K | Sell |
5,492
-6,926
| -56% | -$80.5K | ﹤0.01% | 7589 |
|
|
2015
Q1 | $166K | Sell |
12,418
-12,178
| -50% | -$160K | ﹤0.01% | 6374 |
|
|
2014
Q4 | $316K | Buy |
24,596
+11,343
| +86% | +$130K | ﹤0.01% | 5352 |
|
|
2014
Q3 | $144K | Sell |
13,253
-29,970
| -69% | -$343K | ﹤0.01% | 6053 |
|
|
2014
Q2 | $555K | Buy |
43,223
+36,178
| +514% | +$393K | ﹤0.01% | 4256 |
|
|
2014
Q1 | $73K | Sell |
7,045
-835
| -11% | -$9.39K | ﹤0.01% | 6458 |
|
|
2013
Q4 | $77K | Buy |
7,880
+6,208
| +371% | +$55.7K | ﹤0.01% | 5801 |
|
|
2013
Q3 | $17K | Sell |
1,672
-15,522
| -90% | -$152K | ﹤0.01% | 6304 |
|
|
2013
Q2 | $143K | Buy |
+17,194
| New | +$208K | ﹤0.01% | 4943 |
|
Other funds holding IRWD
AC
SCM
VPM
VCM
Citadel Advisors's IRWD Position: Q1 2026 in Review
Citadel Advisors reduced its Ironwood Pharmaceuticals (IRWD) stake by 47% in Q1 2026, selling an estimated $433K and leaving 118,276 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #9743.
Citadel Advisors first reported a position in IRWD in Q2 2013 and has held it in 43 quarters since. The position peaked at $45.4M in Q2 2019. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.
- Citadel Advisors held 118,276 shares of Ironwood Pharmaceuticals worth $415K as of Q1 2026.
- Citadel Advisors sold 105,693 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $433K.
- Ironwood Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9743 holding.
- Citadel Advisors first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Citadel Advisors's Ironwood Pharmaceuticals position peaked at $45.4M in Q2 2019.
- 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.